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Introduction
Vaccination is a deliberate attempt to protect humans against disease. The modern 
history of vaccination began in 1796, when Edward Jenner used a cowpox virus prepa-
ration from a milkmaid for prevention of smallpox. Since the time of Edward Jenner, 
vaccination has controlled the 12 major diseases, at least in some parts of the world: 
smallpox, diphtheria, tetanus, yellow fever, pertussis, Haemophilus influenzae type b 
disease, poliomyelitis, measles, mumps, rubella, typhoid and rabies. The global cam-
paign for smallpox vaccination was very successful so that this disease has disappeared 
from natural occurring of smallpox in the world. Cases of poliomyelitis have been re-
duced by 99% thanks to vaccination in most parts of the world. Vaccinations against 
many other diseases including influenza have made major headway. However, much 
remains to be done. 
 Isolation of the first human influenza A virus in 1933 contributed to the identifica-
tion of the cause of previous epidemics and pandemics of respiratory disease, as well 
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Vaccination is one of the most effective and cost-benefit interventions that prevent the mortal-
ity and reduce morbidity from infectious pathogens. However, the licensed influenza vaccine 
induces strain-specific immunity and must be updated annually based on predicted strains 
that will circulate in the upcoming season. Influenza virus still causes significant health prob-
lems worldwide due to the low vaccine efficacy from unexpected outbreaks of next epidemic 
strains or the emergence of pandemic viruses. Current influenza vaccines are based on im-
munity to the hemagglutinin antigen that is highly variable among different influenza viruses 
circulating in humans and animals. Several scientific advances have been endeavored to 
develop universal vaccines that will induce broad protection. Universal vaccines have been 
focused on regions of viral proteins that are highly conserved across different virus subtypes. 
The strategies of universal vaccines include the matrix 2 protein, the hemagglutinin HA2 stalk 
domain, and T cell-based multivalent antigens. Supplemented and/or adjuvanted vaccina-
tion in combination with universal target antigenic vaccines would have much promise. This 
review summarizes encouraging scientific advances in the field with a focus on novel vaccine 
designs. 
Keywords: Universal vaccines, M2 protein, Stalk domain, T cell immunity, Supplemented vac-
cination
New vaccines against influenza 
virus
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as the development of influenza vaccines [1,2]. Influenza vi-
rus infections can occur in wild animals and livestock as well 
as in all age groups of human populations. The resulting ill-
ness substantially contributes to work and school time losses, 
increases in influenza-related hospitalizations, and deaths 
[3-5]. 
 Influenza virus contains eight segmented negative sense 
RNA genomes within the lipid-bilayer envelope, which be-
longs to the family Orthomyxoviridae. There are three distinct 
types of influenza virus, designated A, B, and C, with types A 
and B of influenza viruses being the major pathogens in hu-
mans. Influenza A viruses occur in birds, humans, horses and 
other species, whereas types B and C are primarily found in 
man. The envelope surface of the influenza virus has viral 
proteins. The hemagglutinin (HA) surface protein is respon-
sible for attachment of the virus to sialic acid-containing re-
ceptors and viral entry by membrane fusion. The neuramini-
dase (NA) surface protein is a receptor-destroying enzyme 
which plays important roles in viral release and cell-to-cell 
spread [6,7]. Influenza A viruses can be further divided into 
different subtypes of HA and NA. There are 17 HA subtypes 
of influenza virus whereas 9 subtypes of NA are known to be 
present [8]. 
Licensed Influenza Vaccines
Conventional inactivated influenza vaccines
The first vaccines using whole- inactivated influenza virus 
were approved for use in the United States in 1945 [9,10]. In-
activated influenza A and B virus vaccines have been exten-
sively used in humans. The vaccines consist of purified virus 
that has been chemically inactivated with formalin or β-pro-
piolactone. Influenza B viruses, the H1 and H3 subtypes of 
influenza A viruses can cause epidemic infections in the hu-
man population. Therefore, current vaccines against influen-
za epidemics contain two influenza A subtypes (H1N1 and 
H3N2) and one or two variants of influenza B virus. The com-
position of the trivalent vaccine contain two influenza A sub-
types (H1N1 and H3N2) and one variant of influenza B virus, 
which is based on the strains of virus that are expected to cir-
culate in the human population during the winter flu season. 
The influenza A subtypes of vaccine strains are adapted to 
grow in embryonated eggs, or may be reassortant viruses con-
taining HA and NA of strains needed for vaccination and oth-
er remaining genes (polymerase basic protein [PB] 1, PB2, 
polymerase acidic protein [PA], nucleoprotein [NP], M1-M2, 
NS) which encode the internal proteins from A/Puerto Ri-
co/8/34 (PR8) (H1N1) virus which confer high growth capac-
ity in eggs [11]. 
 Since the dissolution of the lipid envelope still retain the 
major antigen HA protein and its immunogenicity with re-
duction in reactogenicity, detergent mediated disrupting 
(splitting) influenza viruses to produce subvirion prepara-
tions has been most commonly used in recent vaccines. Al-
though whole-virus vaccines are still in use in some countries 
and are highly effective, most vaccines manufactured since 
the 1970s have been ‘split’ preparations [12-15]. 
Live attenuated influenza virus (LAIV) vaccines
Another platform of influenza vaccines was developed to over-
come the variable efficacy of the inactivated vaccine, its short 
duration of protective immunity, and low capacity to induce 
local or cellular immunity. LAIV vaccines administered via 
nasal spray (FluMist) have been successfully developed. These 
LAIV strains have the properties with cold-adapted (ca) (i.e., 
they replicate efficiently at 25°C, a temperature that is restric-
tive for replication of most wild-type viruses); temperature-
sensitive (ts) (i.e., they are restricted in replication at 37°C or 
39°C); and are attenuated (att) to prevent illness. LAIV is a re-
assortant of internal proteins of a master donor virus and sur-
face proteins (HA, NA) of a wild-type influenza virus. The 
strains of A/Ann Arbor/6/60 and B/Ann Arbor/1/66 were de-
veloped as master donor viruses which acquired the ca, ts, 
and att phenotypes as a result of multiple mutations in the 
gene segments that encode internal viral proteins [16].
 The efficacy of LAIV is relatively high in children compared 
to the inactivated vaccines [17,18]. Intranasal delivery of LAIV 
is likely to induce both serum IgG and mucosal IgA antibod-
ies [19]. Unlike inactivated vaccines, LAIV evokes mucosal 
and systemic humoral and cellular immunity against native 
HA and NA glycoproteins similar to those by natural influen-
za infection. LAIV is considered to be safe and well tolerated 
in children aged over 2 year and adults, but some concerns 
have been raised regarding its safety in younger children and 
subjects with previous asthma or recurrent wheezing [20,21]. 
However, LAIV is less effective in adults, and thus it is not ap-
proved for use in persons over the age of 50, and inactivated 
split vaccines are recommended for adult populations [18,22].
 Currently, five seasonal LAIV backbone strains reached re-
gulatory approval status: A/Len/134/17/57, A/Len/134/47/57, 
B/USSR/60/69, A/Ann Arbor/6/60, and B/Ann Arbor/1/66. 
With the exception of the A/Len/134/47/57 strain, all are pres-
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ently used as master donor strains in the production of sea-
sonal LAIV vaccines. LAIV is licensed under the trade name 
FluMist in the United States and Canada, and Fluenz in Eu-
rope. Early animal experimental data suggest that a new class 
of ‘replication-deficient vaccine’ could be developed in the 
more distant future, with the plausibility of combining the 
contrasting theoretical advantages of both LAIV and the in-
activated vaccines [23].
Quadrivalent influenza vaccines
Circulating influenza viruses are either Yamagata-like or Vic-
toria-like strain. Unfortunately, approximately 2% of the type 
B influenza viruses matched the vaccine strain (called the 
“Victoria” strain) during the 2007-2008 influenza season in 
the United States. The following season, 2008-2009, only 17% 
of type B influenza detected by surveillance matched the vac-
cine strain which was the “Yamagata” strain. Type B viruses 
of a strain different than the vaccine can circulate, causing 
disease due to a mismatch on the type B strain. Vaccine man-
ufacturers have been working on a “quadrivalent” vaccine 
that contains four strains of influenza to address this type B 
mismatching, which contains two subtype A strains (H1N1, 
H3N2) and two type B strains (Victoria, Yamagata). The first 
quadrivalent LAIV vaccine was MedImmune’s nasal spray 
vaccine, FluMist quadrivalent and licensed by Food and Drug 
Administration (FDA). Sanofi Pasteur also announced the re-
sults of its Phase II and Phase III clinical trials of their inject-
able quadrivalent influenza vaccine. New quadrivalent vac-
cines in addition to the trivalent influenza vaccines are on the 
market. 
Experimental Universal Vaccines 
Influenza viruses are continuously evolving, introducing vari-
ous mutations in particular to the surface major glycoprotein 
HA. Most commonly, these changes result from point muta-
tions in the viral genome RNA encoding HA, and are respon-
sible for emergence of new strains responsible for seasonal 
epidemics. Influenza A viruses sometimes emerge with novel 
surface proteins that are completely unrelated to pre-existing 
human strains, as a result of introduction of new HA and/or 
NA genes from other species. These “major antigenic shifts” 
result in novel antigenic subtypes of the HA and/or NA glyco-
proteins that had not previously infected most of the human 
population, and therefore can spread rapidly causing global 
disease pandemics. Three global pandemics of influenza oc-
curred during the 20th century, which were caused by H1N1 
subtype viruses in 1918, H2N2 viruses in 1957, and H3N2 vi-
ruses in 1968. In addition to the human influenza subtypes, 
avian origin influenza viruses including H5N1, H7N2, H7N3, 
H7N7 and H9N2 subtypes were reported to overcome the 
species barrier and to infect humans [24-29]. There was a re-
cent outbreak and report on significant mortality as a result 
of H7N9 avian influenza virus transmission to humans [30]. 
The continuous emergence of highly pathogenic avian influ-
enza H5N1 viruses in domestic poultry and the repeated cas-
es of direct transmission of avian viruses to humans under-
score a persistent threat to public health [31-35]. The 2009 
outbreak of a new swine-origin H1N1 pandemic virus repre-
sents a good example of how fast a new pandemic virus can 
spread in the human population once it acquires the ability 
to transmit among humans [36,37]. The presently used vacci-
nation programs showed a significant delay in controlling the 
spread of new pandemics. Indeed, the recent experience with 
the 2009 H1N1 virus demonstrates the high priority to devel-
op novel vaccines to overcome the limited efficacy of current 
strain-specific vaccines based on HA as well as improved me-
thods of immunization. 
 A truly universal vaccine should be able to protect against 
all subtypes of influenza A viruses and both lineages of influ-
enza B viruses. However, it would be extremely difficult to de-
velop such a universal vaccine that protects against both types 
of influenza A and B viruses. Due to more variants of influen-
za A types in both humans and animals, developing universal 
vaccines have been focused on influenza A viruses. It would 
be highly promising to develop a vaccine that is broadly cross-
protective compared to currently licensed influenza vaccines. 
The concept behind developing universal vaccines is to uti-
lize the highly conserved antigenic target and to make it im-
munogenic sufficient enough for inducing protective immu-
nity (Table 1). The M2 ion channel protein and the stalk do-
main (HA2) of HA of influenza A virus have been extensively 
investigated as a promising antigenic target for developing a 
universal vaccine.
Universal vaccines based on influenza virus M2
Influenza virus M2
M2 is a pH-dependent proton-selective ion channel protein 
and plays a role during virus entry [38-40]. M2 is a specific 
target of anti-influenza drugs such as amantadine and riman-
tadine [41,42]. The amino acid sequence in the extracellular 
domain of M2 (M2e) is highly conserved among human in-
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fluenza A viruses. For example, the N (amino)-terminal epit-
ope SLLTEVET (residues 2-9) in M2e was found to be con-
served at a rate of 100% among human influenza A virus iso-
lates and approximately over 99% among all influenza A sub-
types [43,44].
M2e conjugate vaccines
The extracellular 23-amino acid residue of the M2 protein 
(M2e) is a poor immunogen in its own. Even mice infected 
with influenza virus do not induce high levels of antibodies 
recognizing M2 (data not shown). Nonetheless, M2e specific 
monoclonal antibodies were shown to reduce the plaque size 
or the growth of some influenza A virus strains in vitro [45-
47]. Passive transfer of M2 monoclonal antibodies was shown 
to protect mice by lowering lung virus titers upon subsequent 
infection with influenza A virus [48,49]. Therefore, induction 
of adaptive anti-M2 immunity would be a cost effective and 
practical strategy for controlling influenza epidemics or pan-
demics.
 Because of low immunogenic property of M2, different ap-
proaches to link M2e peptide to carriers and/or use of potent 
adjuvants were explored. The first study on protection was 
reported with a full-length M2 vaccine expressed in insect 
cells after immunization of mice in the presence of incom-
plete Freund’s adjuvant [50]. This recombinant M2 vaccine 
providedsurvival protection [50]. Since then, many studies 
have reported recombinant M2e fusion constructs using a 
variety of carrier molecules or systems: hepatitis B virus core 
(HBVc) particles [51-53], human papillomavirus L protein vi-
rus-like particles (VLPs)[54], phage Qβ-derived VLPs [55], 
keyhole limpet hemocyanin [56], bacterial outer membrane 
complex [52,57], liposomes [58], and flagellin [59]. Using vari-
ous adjuvants inappropriate for human use, recombinant 
M2e-carrier vaccines were demonstrated to provide protec-
tion against lethal challenge with H1N1, H3N2, and H5N1 in-
fluenza A viruses. In particular, different forms of M2e vac-
cines fused to the HBVc VLPs were shown to induce high lev-
els of anit-M2e antibody responses [43,51,60-62]. However, 
M2e-mediated protection by conjugate vaccines was rela-
tively much weaker than HA-mediated protection [63]. Also, 
M2e antibodies induced by conjugate vaccines were not ef-
fective in binding to the virus [63]. Probably, chemical or ge-
netic fusion of M2e would not be effective in inducing anti-
bodies recognizing M2 in a native conformation on virus [63]. 
 A novel approach was pursued in an attempt to facilitate the 
formation of tetrameric structure of M2e. Genetically linking 
M2e to the tetramer-forming leucine zipper domain of the 
yeast transcription factor general control nondepressible-4 
(GCN4) was demonstrated to form recombinant tetrameric 
M2e vaccines [64]. The recombinant M2e-GCN4 conjugate 
vaccine induced M2e-specific antibody responses conferring 
100% survival protection to vaccinated mice [64]. 
M2e VLP vaccines 
Enveloped VLPs expressing HA and/or NA were demonstrat-
ed to be immunogenic and induce protective immunity [65-
68]. Therefore, we explored an alternative approach to ex-
press M2 proteins in a membrane-anchored form mimicking 
the native conformation of M2. A full-length M2 was present-
ed on influenza M1-derived VLPs containing M2 alone (M2 
VLPs) without HA and NA to avoid the shielding effect by 
large size glycoproteins [69]. Mice vaccinated with M2 VLP 
vaccines induced higher levels of M2e specific antibodies 
than those by whole inactivated influenza virus vaccination 
[70]. In addition, M2e specific antibodies induced by M2 VLP 
vaccination via the intranasal route were cross reactive to and 
protective against diverse subtypes H1N1, H3N2, and H5N1 
influenza viruses [69,70]. However, the wild type M2 protein 
Table 1. Viral antigenic targets of influenza vaccines
Viral protein Targeted site Proposed mechanism(s) of protection
Hemagglutinin (HA1) Receptor binding globular head 
   domain
Strain specific neutralizing antibodies block the virus entry; weak cellular immunity
Hemagglutinin (HA2) Stalk domain with fusion 
activity
(Non-neutralizing) antibodies, inhibition of fusion, maturation of the HA, and antibody dependent  
   cell-mediated cytotoxicity
Matrix 2 ion channel 
(M2)
Ectodomain of M2 (M2e) Non-neutralizing antibodies, alveolar macrophages, Fc receptor, antibody dependent natural killer cell activity,  
   complement mediated lysis, antibody dependent cell-mediated cytotoxicity, CD4 and CD8 T cell mediated protection
Nucleoprotein (NP) T-cell epitopes Cell lysis by CD8+ cytotoxic T-lymphocytes (CTL), CD4+ T lymphocyte mediated cytolysis
Neuraminidase (NA) Conserved sialidase active site Non-neutralizing antibodies, Inhibition of virus release, virus spread
Matrix (M1) T-cell epitopes Cell lysis by CD8+ CTL, CD4+ T lymphocyte mediated cytolysis
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was incorporated into VLPs at low levels similar to those in 
influenza viruses [69]. The levels of M2 specific antibodies 
were relatively very low and substantial weight loss was ob-
served in M2 VLP alone immunized mice after lethal chal-
lenge [69]. 
 There is another caveat in developing truly universal vac-
cines based on M2e. There are few amino acid variations de-
pending on the host species (human, avian, swine, equine, 
and other hosts) where influenza viruses were isolated [43,44]. 
The five amino acids within the residues 10-20 of M2e (under-
lined residues) were observed to be host restricted: PIRNEW-
GCRCN (aa 10-20, human isolates), PTRNGWECKCS (aa 10-
20, avian isolates), LTRNGWGCRCS (aa 10-20, avian origin 
human isolates), and PIRNGWECRCN (aa 10-20, swine iso-
lates) [44,71]. Therefore, to improve the protective efficacy of 
M2e vaccines, we genetically engineered a tandem repeat of 
M2e epitope sequences (M2e5x) of human, swine, and avian 
origin influenza A viruses, which was expressed in a mem-
brane-anchored form and incorporated in VLPs [71]. In addi-
tion, the chimeric M2e5x construct with the transmembrane 
domain being replaced by that of HA was found to incorpo-
rate heterologous M2e epitopes into VLPs at a several hun-
dred-fold higher level than that on influenza virions or the 
wild type M2 VLPs [71,72]. Intramuscular immunization with 
M2e5x VLP vaccines was highly effective in inducing M2e 
specific antibodies reactive to different influenza viruses, mu-
cosal and systemic immune responses, and cross-protection 
regardless of influenza virus subtypes in the absence of adju-
vant. Importantly, immune sera were found to be sufficient 
for conferring protection in naïve mice, which was long-lived 
and cross protective. Anti-M2e antibodies induced by heter-
ologous M2e5x VLP immunization conferred a wider range 
of cross reactivity to influenza virus at higher levels than those 
by live virus infection, homologous M2e VLPs, or M2e mono-
clonal antibody 14C2 [72]. As a protective mechanism via M2e-
mediated immunity, Fc receptors were found to be important 
for mediating protection by immune sera from M2e5x VLP 
vaccination [72]. Thus, molecular designing and presenting 
M2e immunogens on the surfaces of VLPs provide a promis-
ing platform for developing universal influenza vaccines with-
out using adjuvants, which can be more effective in inducing 
protective M2e immunity than natural virus infection and 
further supports an approach for developing an effective uni-
versal influenza vaccine.
 M2e antibodies have virus non-neutralizing property. M2e 
based immunity alone is infection-permissive and is difficult 
to eliminate disease symptoms so far even in animal models. 
A desirable universal influenza vaccine should be able to di-
minish both morbidity and mortality. A novel approach is to 
use such vaccines of conserved antigenic targets as adjunct 
to current vaccine formulations with a variable antigenic tar-
get HA. In this regard, use of M2e-based VLP vaccines as a 
supplement could significantly improve the efficacy of cross 
protection by HA-based current vaccines. Wild type M2 pre-
sented on VLPs in a membrane-anchored form was found to 
significantly improve cross protection when used in combi-
nation with inactivated whole viral vaccine in mice [70]. Mice 
that were intranasally immunized with a mixture of an inacti-
vated virus and wild type M2 VLP were protected against a 
low dose of challenge virus from both mortality and morbidi-
ty. In addition, M2 VLP-supplemented inactivated influenza 
virus vaccine (A/PR/8/34, H1N1) conferred broad cross pro-
tection to the immunized mice against lethal challenge with 
2009 H1N1 pandemic virus, heterosubtypic H3N2, or H5N1 
influenza viruses [70]. The concept of M2 VLP supplementa-
tion to improve cross protection was extended to the seasonal 
influenza split vaccines as well as to the more commonly used 
route of intramuscular immunization (unpublished data). 
Intramuscular immunization with H1N1 split vaccine (A/
California/07/2009) supplemented with heterologous tan-
dem repeat M2e5x VLPs induced M2e specific humoral and 
cellular immune responses contributing to improved cross 
protection of licensed split vaccines. More importantly, sup-
plementation of M2e5x VLPs was able to shape the host re-
sponses to the split vaccine in the direction of T helper type 1 
responses inducing dominant IgG2a isotype antibodies as 
well as interferon gamma (IFN-γ) producing cells in systemic 
and mucosal sites (unpublished data). These recent new ap-
proaches support evidence that supplementation of split vac-
cines with M2e5x VLPs is a promising new vaccination for 
overcoming the limitation of strain-specific protection by cur-
rently marketed influenza split vaccines.Ultimately, clinical 
trials should be carried out to validate this supplementation 
method as a potential universal vaccine for human use. 
Influenza M2-mediated immunity
The protective immune mechanisms of the immune respons-
es induced by M2 vaccination remain to be fully elucidated 
and further studies are needed for a better understanding 
(Table 1). Antibody-dependent, natural killer cell mediated 
cytotoxicity was found to be important for conferring protec-
tion by vaccination with M2e-hepatitis B core vaccine [63]. 
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Another M2e-carrier vaccine using Mycobacterium tubercu-
losis heat shock protein 70 (M2e-HSP70359-610) was shown to 
provide protection via alveolar macrophages and Fc receptor-
dependent elimination of influenza A virus-infected cells [73]. 
We demonstrated that dendritic and macrophage cells were 
needed for protection by immune sera of M2 VLP vaccina-
tion in a mouse model since depletion of these cells using 
clodronate-liposomes abrogated the protection [69,70]. Oth-
er studies suggest that M2 antibodies can restrict the growth 
of influenza viruses as shown by inhibiting the plaque size or 
replication of in vitro cultured viruses [45,74,75]. Our recent 
studies also found that Fc receptors played an important role 
in conferring protection by M2e immunity of M2e5x VLP im-
munization [72]. Multiple mechanisms are likely to be involv-
ed in conferring protection against influenza after immuniza-
tion with M2 based vaccines. 
Clinical trials of influenza M2 vaccines
The efficacy of some early recombinant M2e vaccines has 
been tested in human clinical trials. Sanofi Pasteur Biologics 
Co., formerly Acambis (Cambridge, MA, USA) reported the 
safety and immunogenicity of a recombinant vaccine candi-
date, M2e-HBc fusion protein (ACAM-FLU-A) in its Phase I 
trial study [76]. The ACAM-FLU-A vaccine was demonstrated 
to be immunogenic and well-tolerated with no significant 
side-effects. M2e-HBc carrier protein vaccine also conferred 
partial protection of 70% survival from infection by the highly 
lethal avian H5N1 influenza strain in ferrets a more relevant 
animal model. The flagellin-adjuvanted HA fusion protein 
vaccine was tested in a clinical trial and shown to be immu-
nogenic in elderly vaccinees [77]. An M2e-flagellin fusion vac-
cine (STF2.4xM2e) was also tested in healthy young volun-
teers, aged 18-49 as reported in the first Phase I clinical trial 
study by VaxInnate Corp. (Cranbury, NJ, USA) [76,78]. Low 
doses of flagellin-M2 vaccines (0.3 and 1.0 µg doses) were 
found to be safe and tolerated in subjects tested. Also, these 
M2e-flagellin conjugate vaccines were immunogenic in 75% 
vaccinees after the first dose and 96% after the second dose 
[76,78]. However, two high doses (3 and 10 µg doses) of fla-
gellin-M2 vaccines were associated with the appearance of 
adverse effects of illness symptoms in some of the subjects. 
Therefore, toxicity of flagellin adjuvant might be an issue at 
higher doses of vaccines. Development of a safer vaccine 
based on M2 will be needed and VLP-based vaccines can be 
an attractive candidate without using additional adjuvants. 
These clinical trials merit further studies for developing safe 
and effective universal influenza vaccines.
Cross protective immunity by hemagglutinin stalk domain 
(HA2) vaccines 
Functionally, influenza virus HA is composed of a receptor 
binding globular head domain of HA1 and a membrane-fu-
sion inducing stalk domain of HA2 for virus entry [79]. Cur-
rent influenza vaccination is based on immunity to the glob-
ular head domain of HA1 surrounded by variable antigenic 
sites contributing to the generation of numerous escape mu-
tants [80,81]. The failure or low efficacy of influenza vaccina-
tion is primarily due to mutations occurring in the HA1 glob-
ular head domains of predicted influenza virus pathogens 
[82,83]. 
 In an effort to identify conserved epitopes, recent studies 
have provided evidence that the HA stalk domain can be a 
potential target for developing universal vaccines. The se-
quence homology of the HA2 subunit among different sub-
types is in a range of 51-80%, and the sequence conservation 
of HA2 is relatively higher than that of the HA1 subunit do-
main which is in a wider range between 34% and 59% [84]. 
The sequence conservation of the HA2 subunit among influ-
enza virus strains within the same subtype is even higher [84]. 
In particular, specific regions in the HA stalk domains were 
identified to be highly conserved among different subtypes of 
influenza viruses, which can be divided into two main phylo-
genetic groups [8]. The group 1 includes the subtypes of H1, 
H2, H5, H6, H8, H9, H11, H12, H13, H16, and H17. The group 
2 contains the subtypes of H3, H4, H7, H10, H14, and H15. A 
long α-helix domain in the HA2 subunit (the 76-130 amino 
acid region) was shown to have this conservation among dif-
ferent HA subtypes [85,86]. 
 Recent studies demonstrate the feasibility of stalk domain-
based vaccines. The chemically synthesized fusion peptide 
(amino acids 1-38 of HA2) was conjugated to the keyhole lim-
pet hemocyanin and tested in mice as a vaccine [87,88]. Simi-
larly, this vaccine provided survival protection against a low 
dose challenge with homologous and heterologous virus in 
immunized mice but showed severe weight loss, indicating 
its incapability of preventing illness [87,88]. A long α-helix 
HA2 vaccine consisting of the amino acid 76-130 polypeptide 
was coupled to the carrier protein keyhole limpet hemocya-
nin and its vaccine efficacy was tested I a mouse model [85,86]. 
Sera from immunized mice with an α-helix HA2 conjugate 
vaccine showed substantial binding antibodies reactive to 
heterosubtypic viruses [86]. This α-helix HA2 vaccine could 
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confer partial survival protection against heterosubtypic chal-
lenge viruses (A/PR8 H1N1, A/Vietnam/04 H5N1 virus) and 
the homologous virus H3 subtype. Although the HA2 vaccine 
immune sera showed broader cross-reactivity with different 
HA molecules, the breadth was limited to the group 2 HAs 
(subtypes H3, H4, H7, H10, H14, and H15). 
 Using recombinant genetic engineering techniques, head-
less HA constructs that were composed of membrane-proxi-
mal portions of both the HA1 signal peptide region and HA2 
subunits were stably expressed on the cell surfaces [89]. As 
well, these headless HA constructs were intended to avoid 
the highly immunogenic head domain. Co-expression of the 
human immunodeficiency virus (HIV) Gag core protein and 
headless HA protein by transient DNA co-transfections pro-
duced chimeric Gag VLPs containing headless HA molecules 
[89]. Two times vaccinations with DNA constructs (Gag+HA) 
were followed by boost immunization with chimeric head-
less HA VLP vaccines in the presence of Freund’s complete 
adjuvant [89]. Immunization of mice with Headless HA VLP 
vaccines provided protection against homologous challenge 
with moderate body weight loss. The neutralizing activity in 
immune sera of mice with headless HA VLP vaccines was not 
conclusively confirmed [89]. Nonetheless, headless HA (A/
PR8) VLP immune sera were likely to show greater reactivity 
to heterologous strains than the full-length HA vaccine [89]. 
A/Hong Kong/68 headless HA VLP vaccines did not induce 
antibodies cross reactive to different group 1 HAs (subtypes 
H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16). Vaccines 
of influenza virions stripped of HA1 by treatment with acid or 
dithiothreitol were found not to be effective in inducing cross 
reactive antibodies and cross protection compared to the un-
treated control vaccines [90,91]. Possible limitations of these 
approaches include a low yield of headless HA VLPs produced 
by transient DNA transfection, use of Freund’s adjuvant, and 
limited breadth due to the specificity of reactivity to certain 
HA subtypes.
 Heterologous prime-boost immunization strategies may 
elicit cross-reactive anti-HA antibodies. A recent study from 
the Palese group demonstrated that prime-boost immuniza-
tions with chimeric HA influenza vaccine constructs could 
elicit broadly cross reactive stalk-specific antibodies [92]. Mice 
were repeatedly immunized with serial chimeric HA protein 
constructs of H7 HA head domain plus the H3 stalk domain, 
H5 HA head domain plus the H3 stalk domain, and H4 HA 
head domain plus the H3 stalk domain. After challenge of 
mice that were multiple times immunized with chimeric HA 
proteins, the immune sera were found to contain cross pro-
tective antibodies likely targeted to the stalk domain [92]. In-
terestingly, the stalk domain responsive antibodies were in-
duced by H3N2 influenza virus infection but not by immuni-
zation with inactivated influenza virus vaccines [93]. Interest-
ingly, when human subjects who were first primed with an 
H5 HA DNA vaccine were then boosted with an inactivated 
H5 vaccine, substantial levels of anti-HA stalk domain anti-
bodies were elicited, which showed cross neutralizing activity 
against the group 1 viruses [94]. However, no promising and 
effective vaccines capable of inducing antibodies targeted to 
the stalk domain, which are protective regardless of HA sub-
types, have been developed yet. Further development of these 
vaccines based on the stalk domain of HA would likely con-
tribute toward universal influenza vaccines. 
T Cell-Based Vaccines for Heterosubtypic 
Protection
Seasonal influenza viruses undergo continuous mutation in 
the antigenic sites of HA and NA molecules, which allow vari-
ants to escape from the neutralizing antibody responses. Since 
the majority of cytotoxic T lymphocytes (CTLs) can recognize 
relatively conserved viral proteins such as the NP, the PA and 
the matrix 1 protein (M1), they are able to contribute to het-
erosubtypic immunity between different subtypes [95,96]. 
 It has been recognized that CTLs play a key role in elimi-
nating influenza virus infected cells by inducing apoptosis 
through contact-dependent interactions [97]. There is evi-
dence for the role of influenza virus-specific CTLs, which are 
elicited by vaccination or virus infection, in protection against 
infection with influenza A virus of different subtypes (Table 
2). Previous studies have demonstrated that influenza virus-
specific CTLs provide protective heterosubtypic immunity, 
which are confirmed by depletion in influenza virus-infected 
mice or adoptive transfer of influenza virus-specific CTLs into 
naïve mice [95,98,99].
 The majority of T cell-mediated vaccines target highly con-
served internal proteins such as NP, PA and M1 proteins. The 
different approaches for T cell-based vaccine development 
have been used, which include the LAIVs, plasmid DNAs, vi-
ral vectors (modified vaccinia Ankara strain), and VLPs (Table 
2). These T cell-based vaccines can also induce humoral an-
tibody responses. One of popular trial is the use of LAIV which 
can be generated by adaptation at low temperatures. In hu-
mans, LAIV vaccination induced strong IFN-γ-producing 
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CTLs than inactivated influenza vaccine [100]. Of interest, 
conserved NP-, PA-, and PB1-specific CD4 and CD8 T cells 
generated after attenuated cold-adapted H3N2 or a 2009 
pandemic H1N1 vaccine conferred protection against het-
erosubtypic lethal challenges in mice [101,102].
 In addition to LAIV, DNA vaccination can be another can-
didate. A previous study has shown that NP DNA vaccination 
increased CTL precursor frequency and provided better pro-
tection in NP DNA-immunized mice compared to mice vac-
cinated with HA DNA in response to challenges with heterol-
ogous influenza viruses [103,104]. Furthermore, other vaccine 
types have been described to induce influenza virus specific-
CTL responses. Vaccination with complex adenovirus vector 
encoding H5, N1 and M1 genes induced antigen specific CTLs 
that were able to producing IFN-γ [105]. Recently, mice that 
were immunized with VLPs containing HA protein derived 
from PR8 were protected against homologous and hetero-
subtypic influenza virus infections and this protection was 
dependent on HA-specific CTL responses [106].
 There is evidence that virus-specific CTLs can afford pro-
tection against a variety of influenza virus subtypes, but it is 
also important to consider generating antigen-specific anti-
body responses directed to external proteins HA and NA as 
well as internal proteins. Interestingly, CTLs specific for NP 
protein cooperatively synergize protective immunity with 
non-neutralizing antibodies [107,108]. Thus, it suggests that 
generation of both antigen-specific CTLs and antibodies is 
prerequisite for robust protective immunity against hetero-
subtypic influenza virus infections in human.
 The replication defective vaccinia Ankara strain (MVA) ex-
pressing M1 and NP from A/Panama/2007/1999 virus (H3N2) 
(MVA-NP+M1) was tested in recent clinical trials [109]. Indi-
viduals were immunized with MVA-NA+M1 or unimmunized 
prior to challenge with A/Wisconsin/67/2005 H3N2 virus. 
Higher levels of influenza-specific CTL responses were ob-
served compared to unvaccinated controls. Also, those who 
were vaccinated showed fewer days of virus shedding than 
unvaccinated control subjects. However, fewer numbers of 
subjects were enrolled and further validation with a larger 
number of subjects is warranted. 
Roles of Innate Immunity in Vaccination 
Recognition of microbial pathogens and vaccine antigens is 
an essential element for initiating adaptive immune respons-
es as well as determining the quality of resulting host immune 
responses. Dendritic cells (DCs) and macrophages play a crit-
ical role in inducing protective adaptive immune responses 
of both T and B cells. We found that presenting HA antigen 
on VLPs was significantly much more effective in inducing 
protective T cell and B cell responses than the soluble HA pro-
tein antigen [110]. Effective induction of protective immunity 
by antigens in a VLP form is probably because particulate an-
tigens are more likely to activate innate immune cells such as 
DCs. 
 Antigen-presenting cells (APCs) such as DCs and macro-
Table 2. The evidence of the role of T cells in heterosubtypic immunity
Infection or vaccination Challenge Approach Comments
H1N1 [95] H3N2 Depletion of T cells CTLs reduced viral infection and conferred protective heterosubtypic  
   immunity in mice
NP Vaccina virus [98] H3N2, H1N1 Adoptive transfer of T cells NP specific-CD8 T cells reduced virus replication and protected mice  
   against a lethal influenza virus infection in mice
H3N2 [99] 2009 H1N1 Depletion of CD8 T cells CTLs conferred protection against 2009 H1N1
LAIV H1N1 [100] Intracellular cytokine staining of CD4  
   and CD8 T cells
IFN-γ-producing T cells in blood were increased 10 days post vaccination  
   in humans
LAIV H3N2 [102] H1N1 Tetramer staining and depletion of CD4  
   or CD8 T cells
Depletion of CD8 T cells abrogated protection against a lethal  
   heterosubtypic influenza infection in mice
NP DNA (H1N1) [103] H3N2 Adoptive transfer of NP specific T cells NP-specific CTLs conferred protection in naïve mice
NP DNA plasmid [104] H1N1, H5N1 Depletion of CD4 or CD8 T cells Depletion of both CD4 and CD8 T cells reduced survival rate after mice  
   challenged with influenza viruses in mice
HA-VLPs [106] H1N1, H2N2 Depletion of CD8 T cells Survival rate was diminished after administration of anti-CD8 depletion 
   antibody in mice
MVA-NP+M1 (H3N2, A/ 
   Panama/2007/1999) [109]
H3N2 (A/Wisconsin/ 
   67/2005)
CTLs Influenza virus specific CTL and virus shedding were determined in humans
CTL, cytotoxic T-lymphocyte; NP, nucleoprotein; LAIV, live attenuated influenza virus; IFN-γ, interferon gamma; VLP, virus-like particle.
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phages prominently express toll-like receptors (TLRs) which 
recognize pathogen, vaccine antigen, or adjuvant components. 
APCs play critical roles in activating innate immunity by rec-
ognizing and capturing pathogens or vaccine antigens at the 
site of infection or vaccination via receptors such as TLRs. 
Antigen-loaded APCs initiate the events of inducing the acti-
vation of adaptive T and B cells [111]. In cases where vaccine 
antigens (such as subunit vaccines) are not effective in stimu-
lating APCs, adjuvants should be included in the vaccine for-
mulation to activate APCs. Some compounds enhancing an-
tigen depot or activating innate immunity by interacting with 
pathogen recognizing receptors (PRRs) such as TLRs have 
shown some promise. For example, alum, MF59, or AS04 (TLR 
agonist) adjuvants are often added to the subunit vaccine for-
mulations. But live attenuated (cold-adapted) influenza vac-
cines are likely to activate TLR3 and 7 during viral replication 
intra-cellularly leading to the up-regulation of inflammatory 
cytokines [112], and thus adjuvants are not needed. Also, the 
live attenuated yellow fever vaccine, one of the most effective 
vaccines, was demonstrated to activate multiple DC subsets 
via TLRs 2, 7, 8, and 9 [113]. Activated DCs up-regulate co-
stimulatory molecules through receptor-mediated recogni-
tion of a pathogen or vaccine antigen and can elicit the differ-
entiation of naïve T cells into different effector T cells leading 
to the generation of cytotoxic CD8 T cells and activated B cells 
[111]. 
 B cells are one of the important adaptive immune cells. 
Previous studies suggest that follicular B cells express TLR 1, 
2, 4, 7, and 9. These B cells also showed proliferative respons-
es and isotype switching upon the in vitro stimulation with 
TLR2 (Pam3Cys), TLR3 [poly(I:C)], TLR4 (lipopolysaccharide 
[LPS]), TLR7, and TLR9 agonists [114]. There have been con-
troversies concerning whether TLR signaling is essential for B 
cell responses after vaccination. The addition of TLR9 ligand 
CpGs to B cells in vitro cultures induced the production of Ig-
G2a, IgG2b and IgG3 antibodies [115]. An innate adaptor sig-
naling molecule, myeloid differentiation factor-88 (MyD88), 
is known to be a key adaptor componentfor activation from 
the most TLRs except the TLR3 [116]. MyD88-deficient mice 
have been shown to have a defect in inducing T helper type 1 
immune responses to ovalbumin plus complete Freund ad-
juvant [117]. Importantly, we found that MyD88-deficient 
mice showed a significant defect in generating T helper type 
1 isotype switched antibodies, and interferon (IFN-γ) secret-
ing T cell responses as well as for eliciting long-lived antibody 
secreting plasma cells and protective immunity after vaccina-
tion with influenza VLP vaccines [118]. Better understanding 
of stimulating innate immune components by vaccine anti-
gens will provide informative insight into developing effective 
and safe vaccines. 
 Initially, TLRs were recognized as a family of PRR host cell 
proteins that recognize a wide range of pathogen-associated 
molecular patterns (PAMPs) in the microbial pathogens or 
vaccine antigens [116,119]. To date, 10 and 13 functional TLRs 
have been identified in humans and mice, respectively. TLR1, 
TLR2, TLR4, TLR5, TLR6, and TLR11 are expressed on the 
host cell surface. TLR3, TLR7, TLR8, TLR9, and orphan recep-
tor TLR13 are expressed within intracellular compartments 
such as endosome and recognize nucleic acids [116,120]. TLR1, 
TLR2, and TLR6 recognize pathogen-derived molecules such 
as lipoproteins. TLR3 binds to double-stranded (ds) RNAs 
that are present in many RNA viruses including influenza vi-
rus. TLR4 recognizes bacterial LPS, fusion protein of respira-
tory syncytial virus, fibronectin, and heat-shock proteins. 
TLR5 is known to recognize bacterial flagellin molecules. 
TLR7 and TLR8 are activated by single-stranded (ss) RNA 
molecules that are present in RNA viruses such as influenza 
virus whereas TLR9 recognizes bacterial unmethylated DNA 
molecules. Once TLRs recognize various components of vac-
cine antigens or microorganisms including viruses, inflam-
matory cytokines are produced, which initiate the activation 
of signaling cascade leading to the induction of adaptive im-
mune responses to pathogens or vaccine antigens. 
 Another important family of PRRs includes the C-type lec-
tin receptors (CLRs), cytosolic proteins such as NOD-like re-
ceptors (NLRs) and cytoplasmic RNA helicase retinoic acid 
inducible gene I (RIG-I) or melanoma differentiation associ-
ated gene 5 (named RIG-I like receptors, RLRs) [121]. The 
representative CLRs are DC-specific ICAM-3 grabbing non-
integrin and DC-associated C-type lectin-1 (dectin-1), both 
of which play key roles in inducing immune responses in re-
sponse to fungal, bacterial or virus pathogen molecules. NLRs 
are expressed intracellulary and respond to various PAMPs to 
trigger inflammatory responses [121]. 
 TLRs are expressed on various immune cells including ma-
crophages, DCs, B cells, specific T cells and even expressed on 
non-immune cells such as fibroblasts and epithelial cells [114, 
122,123]. All TLRs except TLR3 use the downstream adap tor 
molecule MyD88, whereas TLR3 and TLR4 in part use Toll 
receptor-associated activator of interferon (TRIF). After TLRs-
ligand interaction, TLR activation results in triggering of down-
stream signaling cascades through the engagement of signal-
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ing intermediates, MyD88, Toll-interleukin (IL)-1 receptor-
associated-protein (also known as MAL), TRIF, Toll receptor-
associated molecule, IL-1 receptor associated kinase, and tu-
mor necrosis factor receptor-associated factor 6. TLR ligation 
can result in activation of transcription factors (IRF3, IRF7, 
activator protein-1, nuclear factor-κB) and consequently pro-
duce the proinflammatory cytokines and chemokines. Fur-
thermore some TLRs (TLR3, 4, 7, 8, 9) are capable of inducing 
type 1 interferons (IFN-α/β) to elicit antiviral responses [116]. 
Vaccine Adjuvants
Adjuvants are used as vaccine additives to lower antigen loads 
in a vaccine or to increase vaccine efficacy [124]. Adjuvants 
modulate host immune responses and magnify immunoge-
nicity of the vaccine. In general, influenza vaccine such as split 
vaccine or live attenuated vaccine can elicit host immune re-
sponses in primed healthy individuals without adjuvants. 
However, in the elderly or immune-compromised popula-
tions, adjuvants are needed to increase responsiveness to the 
vaccine [125]. Adjuvants have a critical role in inducing in-
nate, adaptive and memory immune responses to some vac-
cine antigens. 
 Representative adjuvants and their possible action mecha-
nisms are listed in the Table 3. Aluminium adjuvant (Alum) is 
the most commonly used vaccine adjuvants. It has been used 
for more than 70 years because of its safety and capacity of 
making antigen depot [126]. Alum adsorbs the vaccine anti-
gen and makes the antigen stay longer in the injection site, so 
that immunogenicity of the antigen is increased. In an im-
munological mechanism study, alum was shown to activate 
NALP3 inflammasome and induce IL-1β production to stim-
ulate the innate immune system. Alum is likely to induce T 
helper type 2 immune responses to co-administered antigens 
in humans [127].
 MF59 is an oil-in-water emulsion type of adjuvants, and 
composed of squalene, polysorbate 80, sorbitan trioleate, tri-
sodium citrate dehydrate, citric acid monohydrate and water 
for injection [128]. MF59 adjvuant is used in influenza vac-
cine (Fluad) and pandemic flu vaccine. Use of MF59 adjvuant 
resulted in stronger antibody responses and vaccine antigen 
dose sparing effects [129]. MF59 stimulates cells in the sites of 
injection to express chemokines and cytokines. These che-
mokines and cytokines recruit innate immune cells and APCs. 
Some antigen presenting cells subsequently uptake antigen-
MF59 complex and migrate to draining lymph nodes for the 
induction of adaptive immune responses [130,131]. AS03 is a 
modified form of MF59 and is an oil-in-water emulsion with 
a tocopherol. This form of adjuvant was used in pandemic 
influenza vaccine (Pandemrix) [132]. TLR agonists are con-
sidered as potential adjuvants, so many different kinds of TLR 
agonists have been tried in experimental animal models and 
clinical trials. AS04, which contains Alum and monophos-
phoryl lipid A (MPL), is a licensed adjuvant in hepatitis B vi-
rus (HBV) vaccine (Fendrix) [133] and human papillomavi-
rus vaccine (Cervarix) [134]. MPL is a detoxified form of LPS, 
which is a TLR4 agonist. It can activate immune cells such as 
monocytes and myeloid dendritic cells directly to induce im-
mune responses to the vaccine antigen [124]. Flagellin, a TLR5 
agonist and a motor apparatus of bacteria, can induce mixed 
T helper types 1 and 2 immune responses. Flagellin-antigen 
fusion proteins were developed to magnify the vaccine and 
Table 3. Various adjuvants used in vaccines
Adjuvants Major components Mechanism of action Used vaccines
Alum Aluminium hydroxide Antibodies, T helper type 2, adsorb antigen, NARP3 inflammasome Various human vaccines
MF59 Oil in water emulsion Antibodies, T helper types 1 and 2, stimulate immune cells Influenza, pandemic flu
AS03 Oil in water emulsion with tocopherol Antibodies, T helper types 1 and 2, stimulate immune cells Pandemic flu
AS04 MPL (TLR4 agonist) + Alum Antibodies, T helper type 1, TLR4 signaling stimulation, NLRP3 inflammasome HBV, HPV
Flagellin Flagellin (TLR5 agonist) or  
   Flagellin-antigen fusion protein
Antibodies, T helper types 1 and 2, TLR5 signaling stimulation Clinical trial
Imiquimod TLR7 agonist Antibodies, T helper type 1, TLR7 signaling stimulation Clinical trial
CpG DNA TLR9 agonist Antibodies, T helper type 1, TLR9 signaling stimulation Clinical trial
QS21 Saponin from American barks Antibodies, T helper types 1 and 2, stimulate immune cells, deliver antigen to  
   cytoplasm 
Clinical trial
Ginseng extract Extract from Panax ginseng Antibodies, T helper types 1 and 2, stimulate immune cells Clinical trial
Alpha-GalCer Extract from marine sponge Antibodies, T helper types 1 and 2, stimulate immune cells Clinical trial
MPL, monophos phoryl lipid A; TLR, toll-like receptor; HBV, hepatitis B virus; HPV, human papillomavirus.
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adjuvant effects [135]. Imiquimod, a TLR7 agonist, and CpG 
DNA, a TLR9 agonist, stimulate plasmacytoid dendritic cells 
which can produce type 1 interferons to induce immune re-
sponses to intracellular pathogens such as virus [124]. 
 Recently, natural substances have received attention as a 
potential adjuvant compounds. QS21, derived from Ameri-
can bark, is a saponin-based adjuvant. QS21 can stimulate 
dendritic cells directly and also destabilize the membrane of 
the endosome to deliver antigen to the cytoplasm, so that it 
can elicit cellular immune responses [136]. Another example 
of the natural adjuvants is an extract from Panax ginseng. It 
induced a balanced T helper types 1 and 2 immune response 
[137]. Many marine organisms, for example, sponge and al-
gae extracts, are also investigated actively in experimental 
and clinical level. Alpha-galactosylceramide (alpha-GalCer), 
an extract from marine sponge, is known to stimulate natural 
killer T cells and induce antibody production, and balanced 
T helper types 1 and 2 immune responses [138]. 
Conclusion
Until now, most licensed influenza vaccines are manufac-
tured by methods that were established more than 50 years 
ago despite recent scientific advances in vaccinology. New 
vaccines against influenza viruses to improve the breadth of 
protection would be feasible but some technical, regulatory, 
and logistical challenges remain to be resolved. 
 Many studies reporting universal influenza vaccines have 
focused on conserved single peptides or proteins as target 
antigens (M2e, HA2 stalk domain, NP, M1) in the presence of 
adjuvants in animal models. These conserved antigenic tar-
gets have relatively weak immunogenicity (Table 1). Experi-
mental vaccines based on the HA2 stalk domain or M2e ex-
ternal domain of ion channel protein are not capable of in-
ducing neutralizing antibodies although some monoclonal 
antibodies binding to the HA2 stalk domain are known to 
have cross neutralizing activity. Immunization with T-cell 
vaccines could provide survival protection but not prevent 
infection. Therefore, the protective efficacy of these candi-
date universal vaccines would be lower than strain-specific 
HA based vaccines of inducing neutralizing antibodies. 
 It is needed to develop new qualitative and quantitative 
methods to define the potency of the vaccine as well as to iden-
tify immune correlates of cross protection. The path to licen-
sure of novel influenza vaccines will require demonstration 
of efficacy in humans. Vaccines that do not prevent infection 
but ameliorate disease will need a larger scale of clinical tri-
als. Public health authorities will evaluate how truly universal 
novel influenza vaccines are. Challenging decisions include 
whom to vaccinate and how often the universal vaccine may 
require updating. 
 As alternative approaches to developing truly universal 
vaccines, supplementation concept will be proven to be fea-
sible by complementing and broadening the efficacy of cur-
rent vaccines based on the strain-specific immunity. We have 
shown that supplementing the whole inactivated virus with 
the conserved M2 VLP vaccine was found to significantly im-
prove the heterosubtypic cross protection [70]. With the emer-
gence of drafting epidemic strains or an outbreak of pandem-
ic, the supplemented vaccination would significantly prevent 
the mortality and ameliorate morbidity. 
 It will provide highly informative insight into developing 
novel new vaccines and adjuvants if we better understand 
the immunological mechanisms how cross protective vac-
cines work and by which certain adjuvants enhance the im-
munogenicity of vaccines. Also, deciphering the roles of in-
nate immune components in contributing to long term pro-
tective immunity will be an important area to be explored for 
designing and developing effective vaccines. In addition, cur-
rent vaccines are mostly given by intramuscular injection us-
ing syringe-needles and administered by medical personnel. 
It is also an important area in vaccine field to develop new 
vaccine technologies and alternative routes of immunization 
such as needle-free skin delivery, oral, nasal, and sublingual 
immunization. 
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